TRK fusions

From Libre Pathology
Revision as of 05:41, 11 September 2018 by Michael (talk | contribs) (→‎Association: ref)
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

TRK fusions are seen in many solid tumours and have targeted drugs.

Genes:

  • TRK1
  • TRK2
  • TRK3

The TRK genes are tyrosine kinase receptors.

Multiple fusion partners for each gene.

Association

  • MASC.
  • Secretory breast carcinoma - ETV6-NTRK3.[1]

Drugs

  • Merestinib.
  • Larotrectinib.
  • Others.

See also

References

  1. ↑ Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.
Retrieved from "https://librepathology.org/w/index.php?title=TRK_fusions&oldid=49357"